Noveris Health Sciences is trading at CA$0.08 and is down -5.88% amid broad biotech weakness and risk-off trading.

  • No new company-specific catalyst was identified for September 15, 2026.
  • The latest corporate update was September 9 shareholder approval of annual-meeting resolutions, not a fresh market-moving announcement.
  • The move remains primarily sector-driven, not a company event; shares closed at CA$0.09 on September 14 after CA$0.10 on September 11, alongside falling major indexes and higher bond yields pressuring the thinly traded shares.